Rivex home search contact us helix biopharma
Rivex Pharma Inc.
 

Osteoarthritis

Overview Osteoarthritis of the Knee Treatment Options

Osteoarthritis (OA), or degenerative joint disease, is the most common form of arthritis. It affects up to 2.7 million Canadians. It is characterized by a breakdown of the joint’s cartilage, which leads to pain and lack of movement. The pain is caused from the mechanical friction caused by bone-to-bone contact. The disease most commonly affects middle-aged to older people. It ranges from mild to severe, and affects hands and weight-bearing joints such as knees, hips and back. There are two forms of this disease. The primary form appears spontaneously without cause but is usually associated with aging. The secondary form is a result of trauma such as fractures or injuries to ligaments, or trauma to the meniscus. It can also occur as a result of another form of arthritis.

OA is thought to affect 20% of the population from ages 45 – 55 and up to 50% of people over 65. It affects virtually everyone over the age of 75. There are many factors that can cause OA. While age is a factor, it is not totally predictive. Obesity may lead to OA simply from the strain that it places on weight-bearing joints. Sports, trauma and work-related activities all can lead to an increased incidence.

ORTHOVISC® and MONOVISC™ (sodium hyaluronate) reduce joint pain and improve joint mobility, safely and effectively providing significant relief from the pain of osteoarthritis (OA) of the knee. ORTHOVISC® and MONOVISC™ supplement the synovial fluid to naturally augment lubrication, cushioning and offer superior protection to the arthritic knee joint.

ORTHOVISC® provides long-term relief with just 3 weekly treatments.

MONOVISC™ was approved in 2009 and offers significant pain reduction from OA of the knee in a single injection.

 
 
 
 
 
 
 
Home | Management | Therapeutic Areas | Links | Products | Search | Contact Us